The estimated Net Worth of Christopher David Ozeroff is at least $525 Thousand dollars as of 22 November 2021. Mr. Ozeroff owns over 50,000 units of ARCA biopharma Inc stock worth over $122,328 and over the last 15 years he sold ABIO stock worth over $22,812. In addition, he makes $380,168 as Senior Vice President, General Counsel, and Secretary at ARCA biopharma Inc.
Sign up
Mr. Ozeroff ABIO stock SEC Form 4 insiders trading
Christopher has made over 8 trades of the ARCA biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of ABIO stock worth $113,000 on 22 November 2021.
The largest trade he's ever made was buying 50,000 units of ARCA biopharma Inc stock on 22 November 2021 worth over $113,000. On average, Christopher trades about 2,758 units every 113 days since 2010. As of 22 November 2021 he still owns at least 50,970 units of ARCA biopharma Inc stock.
You can see the complete history of Mr. Ozeroff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Ozeroff biography
Christopher David Ozeroff is Senior Vice President, General Counsel, Secretary of ARCA biopharma Inc.Previously, Mr. Ozeroff served as the Company’s Executive Vice President of Business Development, General Counsel and Secretary since the merger with Nuvelo. Before the merger, Mr. Ozeroff was one of the founders of ARCA Colorado in September 2004, and had served as its Executive Vice President of Business Development, General Counsel and Secretary since that date. From August 1999, Mr. Ozeroff was previously a partner with the law firm of Hogan & Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings, and licensing. Mr. Ozeroff completed his undergraduate degree at Stanford University and his law degree at the University of Chicago Law School.
What is the salary of Christopher Ozeroff?
As the Senior Vice President, General Counsel, and Secretary of ARCA biopharma Inc, the total compensation of Christopher Ozeroff at ARCA biopharma Inc is $380,168. There are 3 executives at ARCA biopharma Inc getting paid more, with Michael Bristow having the highest compensation of $501,400.
How old is Christopher Ozeroff?
Christopher Ozeroff is 57, he's been the Senior Vice President, General Counsel, and Secretary of ARCA biopharma Inc since 2009. There are 8 older and 4 younger executives at ARCA biopharma Inc. The oldest executive at ARCA biopharma Inc is Dr. Michael R. Bristow M.D., Ph.D., 76, who is the Co-Founder, Pres, CEO & Director.
What's Christopher Ozeroff's mailing address?
Christopher's mailing address filed with the SEC is 10170 CHURCH RANCH WAY, SUITE 100, WESTMINSTER, CO, 80021.
Insiders trading at ARCA biopharma Inc
Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.
What does ARCA biopharma Inc do?
arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.
What does ARCA biopharma Inc's logo look like?
Complete history of Mr. Ozeroff stock trades at ARCA biopharma Inc
ARCA biopharma Inc executives and stock owners
ARCA biopharma Inc executives and other stock owners filed with the SEC include:
-
Michael Bristow,
President, Chief Executive Officer, Director -
Dr. Michael R. Bristow M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Thomas A. Keuer,
Chief Operating Officer -
Christopher Ozeroff,
Senior Vice President, General Counsel, Secretary -
Christopher D. Ozeroff,
Sr. VP, Gen. Counsel & Sec. -
Raymond Woosley,
Director -
Daniel Mitchell,
Director -
Anders Hove,
Director -
Linda Grais,
Lead Independent Director -
Brian Selby,
Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance -
Thomas Keuer,
Chief Operating Officer -
Robert Conway,
Chairman of the Board -
Dr. Debra Marshall FACC, M.D.,
Chief Medical Officer -
C. Jeffrey Dekker,
Chief Financial Officer -
Henderson Group Plc Janus H...,
-
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Peter J Barris,
10% owner -
Healthcare Capital Partners...,
-
Peter W. Sonsini,
10% owner -
Jon Sakoda,
10% owner -
Joshua Makower,
10% owner -
Forest Baskett,
10% owner -
Equity Opportunities Fund I...,
-
Jean Francois Formela,
Director -
Kathryn E Falberg,
CFO and COO -
J William Freytag,
Director -
Mary K Pendergast,
Director -
Patrick M Wheeler,
acting Chief Financial Officer -
Riley Mccormack,
10% owner -
David George Lowe,
Director -
Burton E Sobel,
Director -
Venture Fund Vii L P Atlas,
10% owner -
Richard B Brewer,
Director -
John L Zabriskie,
Director -
Venture Partners Qualified ...,
10% owner -
Ted W Love,
Director -
Funds, Lp Ma Weaver Jacob F...,
-
Jacob Ma Weaver,
-
Fund, Lp Funicular,
-
C. Jeffrey Dekker,
Chief Financial Officer -
Fund, Lp Ma Weaver Jacob Fu...,
-
Funds, Lp Funicular,
10% owner -
James P Flynn,
Director